Device Trial Radar · NCT06828939
Pulmonary Vein Isolation With the Single Shot Endoscopic Ultra-Compliant PFA Balloon for the Treatment of AF
Last checked: Nov 20, 2026Latest source record: Aug 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
100
Planned (sponsor's estimate)
Start
Dec 12, 2024
Primary completion
Mar 31, 2027
Study completion Dec 31, 2027
Sponsor
- Lead sponsor
- CardioFocusNot on our public-company list
- Sponsor type
- Industry
- First posted
- Feb 17, 2025
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a prospective, single-arm First-in-Human study to demonstrate the safety and effectiveness of the CardioFocus OptiShot Pulsed Field Ablation System for catheter ablation of atrial fibrillation (AF). Patients with symptomatic paroxysmal (short-duration) AF who have not had a previous catheter ablation for AF will be considered for the study. Patients will be followed for one year after the initial ablation procedure.
Conditions
- Atrial Fibrillation (Paroxysmal)
Interventions
pulsed field ablationDevice
Pulsed field ablation using a ultra-compliant endoscopic PFA balloon.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Primary Effectiveness Endpoint - Acute Procedure SuccessTime frame: During procedure
- Primary Safety Endpoint - Rate of Primary Serious Adverse EventsTime frame: 7 days (unless otherwise specified)
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Na Homolce Hospital
Prague, Czech Republic, Czechia · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.